Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189213 · ClinicalTrials.gov registry record · NA
Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep
A NA study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02189213 is a NA study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 14 participants.
The verdict
NCT02189213, a NA study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
1 out of 8 children, adolescents, and young adults suffer from an anxiety disorder. Studies over the past decade show that selective serotonin-reuptake inhibitors (SSRIs), a class of medication that treats anxiety in adults, also works well in young adults, children, and adolescents with anxiety disorders, but only for about 50%. 50% will have undergone treatment for several months before it will be established that the medication is not working to treat the anxiety. The purpose of this study is to find a test that will predict treatment outcome from the beginning based on behavioral and biological measures.
Interventions
- DRUG Sertraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189213
The ClinicalTrials.gov registry entry for NCT02189213 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sertraline is the first listed.
NCT02189213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189213 about?
NCT02189213 is a clinical study titled "Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep". 1 out of 8 children, adolescents, and young adults suffer from an anxiety disorder. Studies over the past decade show that selective serotonin-reuptake inhibitors (SSRIs), a class of medication that treats anxiety in adults, also works well in young adults, children, and adolescents with anxiety dis...
What is the current status of trial NCT02189213?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2014-07. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02189213?
The interventions under investigation include: Sertraline (DRUG).
Who is sponsoring clinical trial NCT02189213?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.